Hyogo - JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; 'JCR') today announces that it has implemented a Named Patient Supply Program for IZCARGO for I.V. infusion 10mg (JAN: Pabinafusp Alfa (Genetical Recombination)) for patients with Mucopolysaccharidosis type II.

Mucopolysaccharidosis II is an X-linked recessive lysosomal storage disease caused by a dysfunction of iduronate-2-sulfatase, an enzyme that breaks down glycosaminoglycans (mucopolysaccharides) in the body. It gives rise to a wide range of symptoms, and there is an unmet medical need for treatment of central nervous system symptoms. The Named Patient Supply Program will enable early access to IZCARGO for I.V. infusion 10mg for eligible patients, in certain countries where it is not commercially available yet. IZCARGO for I.V. infusion 10mg is currently only approved in Japan.

JCR has signed an agreement with Clinigen to implement the Named Patient Supply Program. Under the terms of the agreement, Clinigen will manage key elements of the program including regulatory oversight, logistics and access management. Healthcare professionals can obtain details about the IZCARGO Named Patient Supply Program by calling the customer service team at +44 (0) 1932 824 100 or emailing MedicineAccess@ClinigenGroup.com. Patients seeking medical information should contact their physician.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 48-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values - reliability, confidence, and persistence - benefit all our stakeholders, including employees, partners, and patients.

About Clinigen

Clinigen is a global, specialist pharmaceutical services company focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group supports pharmaceutical and biotech companies across the medical product lifecycle, from clinical through to commercial and operates from sites in North America, Europe, Africa and the Asia Pacific. Clinigen has more than 1,200 employees across five continents in 15 countries, and provides access in more than 120 countries every year.

Contact:

Email: ir-info@jcrpharm.co.jp

(C) 2023 Electronic News Publishing, source ENP Newswire